2026 THV Trainings

First name

Last name

Hospital

Email address

Phone number

(If requiring transport to airport/or event venue)

Pick-Up Location Address

Drop-Off Location Address

Passport Number

Allergies details

Other dietary requirements details

Additional Information

I confirm the above information is accurate and consent to be contacted regarding event logistics

Sign up for updates from Edwards Lifesciences

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about products, services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents. Edwards Lifesciences will use your information in accordance with the Edwards Privacy Policy.

Introducing SAPIEN 3 Ultra RESILIA

Building on the benefits of the SAPIEN 3 platform

SAPIEN 3 Ultra valve, powered by RESILIA tissue

*No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.
*RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards Lifesciences in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg. 2015;149:340-345.
† RESILIA tissue tested against tissue from commercially available bovine pericardial from Edwards Lifesciences in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg.

RESILIA tissue reduced calcification when compared to traditional surgical valve tissue treatments¹

RESILIA tissue showed significant improvement in calcium-blocking properties

*RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards Lifesciences in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg. 2015;149:340-345.
*Control valve (6900P) not available for commercial supply in Australia / and or New Zealand

References

Flameng W, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149:340 -5.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705. doi:10.1056/NEJMoa1814052.
Nazif TM, Cahill TJ, Daniels D, et al. Real-world experience with the SAPIEN 3 ultra transcatheter heart valve: a propensity-matched analysis from the United States. Circ Cardiovasc Interv. 2021;14:e010543.
Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13:e008972.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic valve replacement in low-risk patients at five years. N Engl J Med. 2023;10.1056/NEJMoa2307447

Edwards Lifesciences invites you to the 2026 ANZ THV Training Events

.inline-crimson-crimson-54446 { --inline-theme-color: var(--color-crimson); } @media (min-width: 768px) { .inline-crimson-crimson-54446 { --inline-theme-color: var(--color-crimson); } } Introducing SAPIEN 3 Ultra RESILIA

.inline-crimson-crimson-47663 { --inline-theme-color: var(--color-crimson); } @media (min-width: 768px) { .inline-crimson-crimson-47663 { --inline-theme-color: var(--color-crimson); } } Building on the benefits of the SAPIEN 3 platform

.inline-crimson-crimson-88047 { --inline-theme-color: var(--color-crimson); } @media (min-width: 768px) { .inline-crimson-crimson-88047 { --inline-theme-color: var(--color-crimson); } } RESILIA tissue reduced calcification when compared to traditional surgical valve tissue treatments1

.inline-crimson-crimson-52148 { --inline-theme-color: var(--color-crimson); } @media (min-width: 768px) { .inline-crimson-crimson-52148 { --inline-theme-color: var(--color-crimson); } } RESILIA tissue showed significant improvement in calcium-blocking properties

References

Introducing SAPIEN 3 Ultra RESILIA

Building on the benefits of the SAPIEN 3 platform

RESILIA tissue reduced calcification when compared to traditional surgical valve tissue treatments¹

RESILIA tissue showed significant improvement in calcium-blocking properties